- Home
- MAX vs KROS Comparison
MAX vs KROS Comparison
Compare MAX & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAX | KROS |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | 82 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 551.1M | 655.9M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MAX | KROS |
|---|---|---|
| Price | $12.71 | $20.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 15 |
| Target Price | $17.00 | ★ $22.20 |
| AVG Volume (30 Days) | 485.9K | ★ 1.0M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.57 |
| Revenue | ★ $1,123,093,000.00 | $246,718,000.00 |
| Revenue This Year | $30.80 | $6,876.34 |
| Revenue Next Year | $9.28 | N/A |
| P/E Ratio | ★ N/A | $13.67 |
| Revenue Growth | 64.86 | ★ 37798.31 |
| 52 Week Low | $7.33 | $9.12 |
| 52 Week High | $13.92 | $22.55 |
Technical Indicators
Market Signals| Indicator | MAX | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 49.85 | 63.30 |
| Support Level | $12.60 | $20.73 |
| Resistance Level | $13.46 | $22.20 |
| Average True Range (ATR) | 0.52 | 0.99 |
| MACD | -0.06 | 0.09 |
| Stochastic Oscillator | 22.58 | 68.62 |
Price Performance
Historical ComparisonAbout MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.